Vivos Therapeutics (VVOS) Cash from Operations (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Cash from Operations data on file, last reported at 6000000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 57.89% year-over-year to 6000000.0 in Q1 2026; TTM through Mar 2026 was 17463000.0, a 24.88% decrease from a year earlier, with the FY2025 full-year figure at 15263000.0, down 20.18% from the prior year.
• Cash from Operations for Q1 2026 stood at 6000000.0, down from 3763000.0 in the prior quarter.
• Over the last five years, Cash from Operations for VVOS reached as high as 2516000.0 in Q1 2024 and fell as low as 6082000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 3850764.71 across 5 years, with a median of 3539000.0 in 2023.
• Across the five-year window, Cash from Operations soared 52.07% in 2023 and plunged 57.89% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 3013000.0 in 2022, then grew by 10.32% to 2702000.0 in 2023, then decreased by 9.14% to 2949000.0 in 2024, then slipped by 27.6% to 3763000.0 in 2025, then tumbled by 59.45% to 6000000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 6000000.0 in Q1 2026, 3763000.0 in Q4 2025, and 4200000.0 in Q3 2025.